CA2393759A1 - Peptide .beta.-turn mimetic compounds and processes for making them - Google Patents

Peptide .beta.-turn mimetic compounds and processes for making them Download PDF

Info

Publication number
CA2393759A1
CA2393759A1 CA002393759A CA2393759A CA2393759A1 CA 2393759 A1 CA2393759 A1 CA 2393759A1 CA 002393759 A CA002393759 A CA 002393759A CA 2393759 A CA2393759 A CA 2393759A CA 2393759 A1 CA2393759 A1 CA 2393759A1
Authority
CA
Canada
Prior art keywords
alkyl
heteroatoms
ring
product
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002393759A
Other languages
French (fr)
Inventor
Adam Golebiowski
Sean Rees Klopfenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2393759A1 publication Critical patent/CA2393759A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The subject invention involves compounds having structure (I), wherein: (a) R1 is hydrogen or alkyl; and R2 is selected from hydrogen, alkyl, aryl, heterocyclyl, carboxy and its esters and amides; or R1 and R2 are attached a nd are together alkylene or heteroalkylene; (b) R4 is selected from aryl, heteroaryl, and .alpha.,.beta.-unsaturated conjugated aryl or heteroaryl; an d (c) R5 is selected from hydrogen, alkyl, aryl, and heterocyclyl; and an optical isomer, diesteriomer, or enantiomer thereof; a salt, hydrate, ester, amide or imide thereof. The subject invention also includes libraries of suc h compounds, and processes for making the subject compounds and libraries.</SD OAB>

Description

PEPTIDE (3-TURN MIMETIC COMPOUNDS AND PROCESSES
FOR MAKING THEM
FIELD OF THE INVENTION
The subject invention relates to novel peptide (3-turn mimetic compounds and processes for making such compounds.
CROSS REFERENCE
This application claims priority under Title 35, United States Code 119(e) from Provisional Application Serial No. 60/172,823, filed December 21, 1999.
BACKGROUND
In peptides, the (3-turn is a subset of the reverse turn and is a common feature of biologically active peptides and proteins; it is widely thought to act as a molecular recognition site for many biological processes. Specific types of (3-turns are classified according to their geometry.
The b-turn is defined as any tetrapeptide sequence with a 10-membered intramolecularly H-bonded ring, in which the Ca to Ca+3 distance varies from 4 to 7~.
R5 i+4 R1 ~ O NH
H N ~2 O'~3 v~ N R4 1+3 i+1 R2 ~N O
O Rs i+2 Depending on f2, y2, f3 and y3 there are many types of b-turn structures described in literature. (See:
Gillespie et al., "Conformational Analysis of Dipeptide Mimetics", Bio of , Vol. 43, (1997), pp.
191-217; Venkatachalam, Biopolymers, Vol. 6, (1968), pp. 1425-36.
The subject invention compounds are mimetics for ~3-turn peptides. Such compounds are useful as probes for the study of molecular recognition events, including enzyme inhibition, cell-cell and cell-matrix interactions. One physical consequence of such conformational constraint of the subject compounds is a limiting of the number of accessible conformational states of the molecules, leading to a better definition of the bioactive conformation of corresponding active peptides.
Information regarding ~3-turn peptides and mimetic compounds can also be found, for example, in the following references: Ball et al., "(3-Turn Topography", Tetrahedron, Vol. 49, No.
17 (1993), pp. 3467-3478; Kahn, "Peptide Secondary Structure Mimetics: Recent Advances and Future Challenges", SYNLETT, (Nov. 1993), pp. 821-826; Hanessian et al., "Design and Synthesis of Conformationally Constrained Amino Acids as Versatile Scaffolds and Peptide Mimetics", Tetrahedron, Vol. 53, No. 38 (1997), pp. 12789-12854.
SUMMARY OF THE INVENTION
The subject invention includes compounds having the structure:

O NH
O

~N ~ ~N R4 NJ

O
wherein:
(a) R1 is hydrogen or alkyl; and R2 is selected from hydrogen, alkyl, aryl, heterocyclyl, carboxy and its esters and amides; or Rl and R2 are attached and are together alkylene or heteroalkylene;
(b) R4 is selected from aryl, heteroaryl, and a,(3-unsaturated conjugated aryl or heteroaryl; and (c) R5 is selected from hydrogen, alkyl, aryl, and heterocyclyl;
and an optical isomer, diesteriomer, or enantiomer thereof; a salt, hydrate, ester, amide, or imide thereof.
The subject invention also includes libraries of such compounds, and processes for making the subject compounds and libraries.
DETAILED DESCRIPTION OF THE INVENTION
As used herein unless specified otherwise, "alkyl" means a hydrocarbon chain which is branched, linear or cyclic, saturated or unsaturated (but not aromatic), substituted or unsubstituted. The term "alkyl" may be used alone or as part of another word where it may be shortened to "alk" (e.g., in alkoxy, alkylacyl). Preferred linear alkyl have from one to about twenty carbon atoms, more preferably from one to about ten carbon atoms, more preferably still from one to about six carbon atoms, still more preferably from one to about four carbon atoms;
most preferred are methyl or ethyl. Preferred cyclic and branched alkyl have from three to about twenty carbon atoms, more preferably from three to about ten carbon atoms, more preferably still from three to about seven carbon atoms, still more preferably from three to about five carbon atoms. Preferred cyclic alkyl have one hydrocarbon ring, but may have two, three, or more, fused or spirocycle hydrocarbon rings. Preferred alkyl are unsaturated with from one to about three double or triple bonds, preferably double bonds; more preferably they are mono-unsaturated with one double bond. Still more preferred alkyl are saturated. Saturated alkyl are referred to herein as "alkanyl". Alkyl unsaturated only with one or more double bonds (no triple bonds) are referred to herein as "alkenyl". Preferred substituents of alkyl include halo, alkyl, aryl, heterocycle, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, alkylamino, arylamino, amide, alkylamide, arylamide, formyl, alkylacyl, arylacyl, carboxy and its alkyl and aryl esters and amides, nitro, and cyano. Also, unsubstituted alkyl are preferred.
As used herein, "heteroatom" means a nitrogen, oxygen, or sulfur atom.
As used herein, "alkylene" means an alkyl which connects two other moieties, "heteroalkylene" means an alkylene having one or more heteroatoms in the connecting chain.
As used herein unless specified otherwise, "aryl" means an aromatic hydrocarbon ring (or fused rings) which is substituted or unsubstituted. The term "aryl" may be used alone or as part of another word (e.g., in aryloxy, arylacyl). Preferred aryl have from six to about fourteen, preferably to about ten, carbon atoms in the aromatic ring(s), and a total of from about six to about twenty, preferably to about twelve, carbon atoms. Preferred aryl is phenyl or naphthyl;
most preferred is phenyl. Preferred substituents of aryl include halo, alkyl, aryl, heterocycle, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, alkylamino, arylamino, amide, alkylamide, arylamide, formyl, alkylacyl, arylacyl, carboxy and its alkyl and aryl esters and amides, nitro, and cyano. Also, unsubstituted aryl are preferred.
As used herein unless specified otherwise, "heterocycle" or "heterocyclyl"
means a saturated, unsaturated or aromatic cyclic hydrocarbon ring (or fused rings) with one or more heteroatoms in the hydrocarbon ring(s). Preferred heterocycles have from one to about six heteroatoms in the ring(s), more preferably one or two or three heteroatoms in the ring(s).
Preferred heterocycles have from three to about fourteen, preferably to about ten, carbon plus heteroatoms in the ring(s), more preferably from three to about seven, more preferably still five or six, carbon plus heteroatoms in the rings(s); and a total of from three to about twenty carbon plus heteroatoms, more preferably from three to about ten, more preferably still five or six, carbon plus heteroatoms. Preferred heterocycles have one ring, but may have two, three, or more, fused or spirocycle rings. More preferred heterocycle rings include those which are one ring with 5 or 6 carbon plus heteroatoms in the ring with no more than three ring heteroatoms, no more than two of which are O and S. Still more preferred are such 5- or 6-ring atom heterocycles with one or two ring atoms being O or S and the others being C; or with one, two or three ring atoms being N
and the others being C. Such preferred 5- or 6-ring atom heterocycles are preferably saturated, unsaturated with one or two double bonds, or aromatic. Such preferred 5- or 6-ring atom heterocycles are preferably a single ring; or fused with a 3- to 6-ring atom hydrocarbon ring which is saturated, unsaturated with one double bond, or aromatic (phenyl); or fused with another such 5- or 6-ring atom heterocyclic ring. Heterocycles are unsubstituted or substituted. Preferred heterocycle substituents are the same as for alkyl.
As used herein unless specified otherwise, "heteroaryl" means an aromatic heterocycle.
Compounds of the Invention The subject invention involves compounds having the following structure:

O NH
O

~N ~ ~N R4 N

O (2) In structure 2, R1 is hydrogen or alkyl. Preferred R1 is alkyl having from 1 to about 12 carbon atoms, more preferably from 1 to about 6 carbon atoms, more preferably still 1 or 2 carbon atoms. Preferred alkyl Rl is unsubstituted or substituted; preferred substituents include aryl, heterocyclyl, amino, alkylamino, arylamino, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, carboxy and its esters and amides; more preferred substituents include phenyl, naphthyl, and heterocyclyl having one ring with 5 or 6 ring atoms including I-3 heteroatoms or two fused rings with 8-10 ring atoms including 1-4 heteroatoms. More preferred Rl is hydrogen.
In structure 2, R2 is selected from hydrogen, alkyl, aryl, heterocyclyl, carboxy and its esters and amides. Alkyl R2 preferably has from I to about 8 carbon atoms, more preferably from 1 to about 4 carbon atoms, more preferably still 1 or 2 carbon atoms. Alkyl R2 is preferably unsubstituted or substituted; preferred substituents include aryl, heterocyclyl, amino, alkylamino, arylamino, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, halo, nitro, cyano, carboxy and its esters and amides; more preferred substituents include phenyl, naphthyl, heterocyclyl having one ring with 5 or 6 ring atoms including I-3 heteroatoms or two fused rings with 8-10 ring atoms including 1-4 heteroatoms, hydroxy, CI-C6 alkoxy, phenoxy, thio, CI-C6 alkylthio, phenylthio, carboxy and its CI-C6 esters and amides. Aryl R2 is preferably phenyl or naphthyl, more preferably phenyl. Aryl R2 is preferably unsubstituted or substituted;
preferred substituents include alkyl, aryl, heterocyclyl, amino, alkylamino, arylamino, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, halo, nitro, cyano, carboxy and its esters and amides; more preferred substituents include CI-C6 alkyl. Heterocycle R2 preferably is one ring having 5 or 6 ring atoms including 1-3 heteroatoms or two fused rings having 8-10 ring atoms including I-4 heteroatoms. More preferred heterocycle R2 is heteroaryl. Heterocycle R2 is preferably unsubstituted or substituted; preferred substituents include alkyl, aryl, heterocyclyl, amino, alkylamino, arylamino, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, halo, nitro, cyano, carboxy and its esters and amides; more preferred substituents include C1-C6 alkyl, phenyl, naphthyl, and heterocyclyl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms or two fused rings with 8-10 ring atoms including 1-4 heteroatoms.
R2 is preferably selected from known a-amino acid side-chains, especially those of a-amino acids which commonly occur in nature.
In structure 2, R1 and R2 may be attached, such attached RI/R2 being alkylene or heteroalkylene. Alkylene R1/R2 preferably has from 1 to about 6 carbon atoms, more preferably from about 2 to about 4 carbon atoms, more preferably still 3 or 4 carbon atoms. Heteroalkylene R1/R2 preferably has from 1 to about 5 carbon atoms, more preferably from 1 to about 4 carbon atoms, more preferably still 2 or 3 carbon atoms; and preferably from 1 to about 3 heteroatoms, more preferably 1 or 2 heteroatoms, more preferably still 1 heteroatom.
Alkylene and heteroalkylene R1/R2 are preferably unsubstituted or substituted; preferred carbon atom substituents include alkyl, aryl, heterocyclyl, amino, alkylamino, arylamino, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, carboxy, and its esters and amides; more preferred carbon atom substituents include hydroxy, C1-C6 alkoxy, phenoxy, thio, CI-C6 alkylthio, phenylthio, carboxy and its Cl-C6 esters and amides; preferred nitrogen atom substituents include Cl-C6 alkyl (unsubstituted or substituted).

In structure 2, R4 is selected from aryl, heteroaryl, and a,(3-unsaturated-conjugated aryl or heteroaryl. Aryl R4 is preferably phenyl or naphthyl, more preferably phenyl.
Aryl R4 is preferably unsubstituted or substituted; preferred substituents include alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halo, vitro, cyano, carboxy and its esters and amides; more preferred substituents include CI-C6 alkyl, phenyl, CI-C6 alkyoxy, and halo. Heteroaryl R4 preferably is one ring having 5 or 6 ring atoms including 1-3 heteroatoms or two fused rings having 8-10 ring atoms including I-4 heteroatoms. Heteroaryl R4 is preferably unsubstituted or substituted;
preferred substituents include alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halo, vitro, cyano, carboxy and its esters and amides;
more preferred substituents include CI-C6 alkyl, phenyl, CI-C6 alkoxy, and halo. Conjugated aryl and heteroaryl R4 preferably includes styryl. Conjugated aryl and heteroaryl R4 are preferably unsubstituted or substituted; preferred substituents include alkyl, alkoxy, aryloxy, alkylthio, arylthio, halo, vitro, cyano, carboxy and its esters and amides; more preferred substituents include CI-C6 alkyl, phenyl, CI-C6 alkoxy, and halo.
In structure 2, RS is selected from hydrogen, alkyl, aryl, and heterocyclyl.
Alkyl RS
preferably has from 1 to about 10 carbon atoms, more preferably from I to about 4 carbon atoms, more preferably still I or 2 carbon atoms. Alkyl RS is preferably unsubstituted or substituted;
preferred substituents include alkyl, aryl, heterocyclyl, amino, alkylamino, arylamino, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, formyl, alkylacyl, arylacyl, halo, vitro, cyano, carboxy and its esters and amides; more preferred substituents include phenyl, naphthyl, and heterocyclyl having one ring with 5 or 6 ring atoms including I-3 heteroatoms or two fused rings with 8-10 ring atoms including I-4 heteroatoms. Aryl RS is preferably phenyl or naphthyl, more preferably phenyl. Aryl RS is preferably unsubstituted or substituted; preferred substituents include alkyl, aryl, heterocyclyl, amino, alkylamino, arylamino, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, formyl, alkylacyl, arylacyl, halo, vitro, cyano, carboxy and its esters and amides; more preferred substituents include CI-C6 alkyl, phenyl, and heterocyclyl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms or two fused rings with 8-10 ring atoms including 1-4 heteroatoms.
Heterocycle RS is preferably one ring having 5 or 6 ring atoms including I-3 heteroatoms or two fused rings having 8-10 ring atoms including I-4 heteroatoms. More preferred heterocycle RS is heteroaryl. Heterocycle RS is preferably unsubstituted or substituted; preferred substituents include alkyl, aryl, heterocyclyl, amino, alkylamino, arylamino, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, formyl, alkylacyl, arylacyl, halo, vitro, cyano, carboxy amid its esters and amides; more preferred substituents include CI-C6 alkyl, phenyl, and heterocyclyl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms or two fused rings with 8-10 ring atoms including 1-4 heteroatoms.
The subject invention includes optical isomers, diasteromers, and enantiomers of the compounds of structure 2. The subject invention includes salts, hydrates, esters, amides, and imides of such compounds.
As used herein, a "salt" is a cationic salt formed at any acidic group (e.g., carboxy group), or an anionic salt formed at any basic group (e.g., amino group) on a compound of structure 2.
Many salts are known. Preferred cationic salts include the alkali metal salts, such as sodium and potassium, alkaline earth metal salts, such as magnesium and calcium, and organic salts, such as ammonium. Preferred anionic salts include halides, sulfonates, carboxylates, phosphates, and the like. Salts of addition may provide an optical center where once there was none.
The compounds of the subject invention, and salts thereof, may have one or more chiral centers. The invention includes all optical isomers of the compounds of structure 2 and salts thereof, including diasteriomers and enatiomers.
The subject invention also includes libraries of compounds having structure 2.
Such libraries can be mixtures of compounds of structure 2 or collections of individual compounds of structure 2.
Processes for Making the Compounds Another aspect of the subject invention is processes for making compounds of structure 2, as generally depicted in Scheme 1.
Scheme 1 O O
HO~N~B°c a, b O~NH
Fmoc'NJ
Fmoc' N

O NH O O NH
O
f-h R~~N~N R4 O~ N R4 ~
HNJ R2~NJ
~ ~O

Orthogonally protected, resin bound piperazinic acid is used. Deprotection reaction is followed by functionalization of the b-nitrogen atom via the Petasis reaction. Subsequent amide bond formation leads to the desired inclusion of R4 and RS substituents. Unblocking of the a-nitrogen, followed by Boc-N protected a-amino acid coupling, deprotection and cyclizative cleavage, introduces the R2 and R1 substituents, and leads to bicyclic product 2.
In step a, hydroxymethylpolystyrene resin is reacted with N-protected piperazinic acid (3) to bind it to the resin. This reaction is preferably carried out, after swelling the resin in DCM, in the presence of Ph3P and DEAD which act as Mitsunobu reagents, in THF solvent. The resin product is preferably filtered and washed several times using one or more of THF, DCM, and MeOH to purify the product.
In step b, the protecting group is removed from the ~3-nitrogen of the resin-bound piperazinic acid to produce 4. This is preferably accomplished by using a solution of TFA and DCM, preferably about 40% TFA, preferably after swelling the resin reactant in DCM. The resin product is preferably filtered and washed several times using DCM and/or MeOH, neutralized, and filtered and washed more to purify it.
In step c, piperazinic ester resin 4 is reacted with R4-boronic acid and glyoxylic acid. This reaction is preferably carried out in DCM solvent, preferably after swelling the resin reactant in DCM. The resin product is preferably filtered and washed several times using DCM and MeOH, to purify it. This reaction step and purification are preferably repeated to increase the yield of the desired product.
In step d, the resin product from step c is reacted with amine RS-NH2. Prior to addition of the amine in this step, the resin reactant is preferable swelled using DMF, contacted with HOBt which acts as an activating agent, followed by contact with DIC which acts as a coupling agent, and is filtered and washed with DMF. After reaction with the amine, the resin product is preferably filtered and washed with DMF.
In step e, the resin product from step d is contacted with piperidine which acts as a deprotecting agent. This step is preferably carried out in a solution of piperidine in DMF, the solution being from about 1 S % to about 30 % piperidine. Resulting resin product 5 is preferably filtered and washed several times in DMF. This step is preferably repeated to increase the yield of the desired product.
In step f, resin product 5 is reacted with a N-protected a-amino acid. This reaction is preferably carried out in the presence of PyBOP which acts as a coupling agent, and then a base DiPEA. Prior to adding the amino acid, the resin reactant is preferably swelled using DMF. The resin product is preferably filtered and washed several times with DMF. This step is preferably repeated.
In step g, the protecting group of the a-amino acid of step f is removed. This is preferably done using a solution of TFA in DCM, preferably about 25% TFA. The resulting resin product is preferably filtered and washed several times with DCM and MeOH.
In step h, the resin product from step g is cleaved from the resin and cyclized to produce product 2. This step is preferably carried out in a solution of from about 5%
to about 20% AcOH in iPrOH, at an elevated temperature of from about 30 °C to about 80 °C for a period of from about 20 h to about 80 h. The cleaved resin is filtered off and washed several times, preferably using MeOH.
The filtrate and washings are preferably combined, concentrated, and dried to give 2 as a solid. The solid product is preferably purified by co-evaporating it several times with chloroform, and then drying under vacuum.
The following non-limiting examples illustrate, in more detail, processes of the subject invention.
Example 1 a) Hydroxymethylpolystyrene resin ( 1.0 g, 1.44 mmol/g, Advanced Chemtech) is swelled in anhydrous dichloromethane (DCM) (6 mL). Triphenylphosphine (Ph3P) (1.13 g, 4.32 mmole) is dissolved in this slurry and the heterogeneous reaction is cooled to 0 °C
under nitrogen. To this gently stirring slurry is added a tetrahydrofuran (THF) (30 mL) solution of Na-Fmoc-Np-Boc-2-carboxypiperazine 3 (1.95 g, 4.32 mmol) and diethylazodicarboxylate (DEAD) (751 mL, 4.32 mmole) over a period of 30 minutes. The reaction is allowed to stir for 72 h, at which point the resin is filtered and washed with THF (3X), DCM (3X), MeOH (3X), then multiple, successive and alternating DCM
and MeOH washes (standard manner).
b) Piperazinic resin ester from step a ( 1.4 g) is swelled in DCM, filtered and treated with a 40% solution of trifluoroacetic acid (TFA) in DCM for 1 h. The resin is filtered and washed with DCM (3X), MeOH (3X), then alternating DCM/MEOH as in (a). The resin bound amine TFA salt is then neutralized with a 10% solution of diisopropylethylamine (DiPEA) in DCM and re-washed in the standard manner.
c) The resin ester 4 from step b is swelled in DCM (10 mL) and to this is added glyoxylic acid (265g, 2.88 mmol) and a boronic acid (2.88 mmol) as a solution in MeOH
(15 mL). The resulting slurry is agitated for 5 h, before filtering the resin and washing with MeOH (3X). The above procedure is repeated again for 16 h, after which the resin is again filtered and washed in the standard manner.
d) The resin ester from step c is swelled in DMF (5 ml) and to this is added hydroxybenzotriazole (HOBt) (1.10 g, 7.2 mmol) followed by diisopropylcarbodiimide (DIC) (907 mg, 7.2 mmol). The reaction is agitated for 3h, after which the resin is washed with dimethylformamide (DMF) (4X). The resin is swelled again in DMF
(10 ml), and to this slurry is added an amine (7.2 mmol). The reaction is allowed to agitate for 15 h. The resin is filtered and washed with DMF (3X) followed by the standard manner wash.
e) The resin ester from step d is treated with 25% piperidine in DMF for 20 min.
The resin is filtered and rinsed with DMF (2X) before repeating. The resin product is filtered and washed in the standard manner.
f) The resin product 5 from step a is swelled in DMF. To this is added a boc-a-amino acid (Boc-AA) (7.2 mmole), benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) (3.74 g, 7.2 mmole) followed by DiPEA ( 1.11 g, 8.64 mmole). The reaction is agitated for 5 h, filtered and rinsed with DMF (3X) in the standard manner.
g) The resin product from step f is treated with 25% TFA/DCM for 1 h. The resin is filtered and washed.
h) The resin product from step g is taken up in 10% acetic acid in isopropanol (AcOH/iPrOH) and heated for 16 h at 50 °C. The resin is filtered off and washed several times using MeOH. The filtrate and washings are combined and concentrated to give an off white solid. The solid as co-evaporated several times using chloroform before being dried under vacuum for 15 h.
Examples 2-7 The following non-limiting exemplary compounds are made using the process of Example 1 by reacting the indicated boronic acids, amines, and boc-a-amino acids therein:

~NH2 O O NH
O O NH H~N~N S
H \ ~,, N J I /
N~N
I O
,.~,'~N~ ~J
H02C O 2a HZN 2b N
I O NH I
O
O O NH H~N~N I W
S ''~~' ~ N ~ ~ F
\ N~N I O
~,,,~ N J / \
W
O
2c 2d I~
~N I~
O NJ
O
O O O NH
H.N~N
,,,,, N ~ / N ~ N W
o N
O ",~~ J
I
~I O w 2e 2f Example Boronic Acid Amine Amino Acid Product phenylboronic acid isoamylamine Boc-Asp (O-tBu)- 2a OH
2-thiopheneboronic mono-Boc-butyl- Boc-Lys(Boc)-OH 2b acid 1,4-diamine Exam,~le Boronic Acid Amine Amino Acid Product benzothiophene-2- 4-aminomethyl- Boc-Tic-OH 2c bornonic acid pyridine S 4-fluoroboronic acid phenethylamine Boc-Phe-OH 2d 6 2-furylboronic acid benzylamine Boc-Phe-OH 2e 7 2-naphthylboronic aniline Boc-Hyp(OBn)-OH 2f acid The above processes of the subject invention are carried out using solid-support resin.
This makes reaction separation and purification of intermediates and final product amenable to automation. Libraries of compounds of structure 2 are readily prepared using the subject invention processes. Automation of the preparation of such libraries is achieved using equipment known to the skilled combinatorial chemist. Such equipment can be used to make libraries which are mixtures of compounds of structure 2 or collections of individual compounds of structure 2 each in an isolated well.
While particular embodiments of the subject invention have been described, it will be obvious to those skilled in the arts that various changes and modifications of the subject invention can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.

Claims (10)

What is claimed is:
1. A compound having the structure:
characterized in that:
(a) R1 is hydrogen or alkyl; and R2 is selected from hydrogen, alkyl, aryl, heterocyclyl, carboxy and its esters and amides; or R1 and R2 are attached and are together alkylene or heteroalkylene;
(b) R4 is selected from aryl, heteroaryl, and .alpha.,.beta.-unsaturated conjugated aryl or heteroaryl; and (c) R5 is selected from hydrogen, alkyl, aryl, and heterocyclyl;
and an optical isomer, diesteriomer, or enantiomer thereof; a salt, hydrate, ester, amide, or imide thereof.
2. The compound of Claim 1 characterized in that (a) R1 is hydrogen or C1-C12 alkyl; and R2 is selected from hydrogen, C1-C8 alkyl, phenyl, naphthyl, and heterocyclyl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms or two fused rings with 8-10 ring atoms including 1-4 heteroatoms;
or R1 and R2 are attached and are together C1-C6 alkylene or heteroalkylene having 1-5 carbon atoms and 1-3 heteroatoms;
(b) R4 is selected from phenyl, naphthyl, styryl, and heteroaryl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms or 2 fused rings with 8-10 ring atoms including 1-4 heteroatoms;
(c) R5 is selected from hydrogen, C1-C10 alkyl, phenyl, naphthyl, and heterocyclyl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms or 2 fused rings with 8-10 ring atoms including 1-4 heteroatoms.
3. The compound of Claim 2 characterized in that:
(a) R1 is hydrogen or unsubstituted or substituted C1-C6 alkyl; R2 is selected from hydrogen, unsubstituted or substituted C1-C4 alkyl, unsubstituted or substituted phenyl, and unsubstituted or substituted heteroaryl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms; or R1 and R2 are attached and together are unsubstituted or substituted C1-C4 alkylene or unsubstituted or substituted C1-C4 heteroalkylene also having one or two heteroatoms;
(b) R4 is selected from unsubstituted or substituted phenyl, unsubstituted or substituted styryl, and unsubstituted or substituted heteroaryl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms; and (c) R5 is selected from hydrogen, unsubstituted or substituted C1-C4 alkyl, unsubstituted or substituted phenyl, and unsubstituted or substituted heterocyclyl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms.
4. The compound of Claim 3 characterized in that:
(a) alkyl R1 substituents are phenyl or heterocyclyl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms;
(b) alkyl R2 substituents are selected from phenyl, heterocyclyl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms, hydroxy, C1-C6 alkoxy, phenoxy, thio, C1-C6 alkylthio, phenylthio, carboxy and its C1-C6 esters and amides;
(c) aryl R2 substituents are C1-C6 alkyl;
(d) heterocyclyl R2 substituents are selected from C1-C6 alkyl, phenyl, and heterocyclyl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms;
(e) alkylene and heteroalkylene R1/R2 substituents are selected from C1-C6 alkyl, hydroxy, C1-C6 alkoxy, phenoxy, thio, C1-C6 alkylthio, phenylthio, carboxy and its C1-C6 esters and amides;
(f) phenyl, heteroaryl, and styryl R4 substituents are selected from C1-C6 alkyl, phenyl, C1-C6 alkoxy, and halo;
(g) alkyl R5 substituents are phenyl or heterocyclyl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms;
(h) aryl and heterocyclyl R5 substituents are selected from C1-C6 alkyl, phenyl, and heterocyclyl having one ring with 5 or 6 ring atoms including 1-3 heteroatoms.
5. The compound of Claim 3 characterized in that R1 is hydrogen or alkyl, R1 and R2 are attached, and R4 is aryl, heteroaryl, or .alpha.,.beta.-unsaturated conjugated aryl or heteroaryl.
6. A process for making a compound having the structure:
characterized in that a piperazinic acid ester or resin-ester is used as a reactant.
7. The process of Claim 8 characterized in that the .beta.-nitrogen of the piperazinic acid ester is functionalized using a boronic acid Mannich-type (Petasis) reaction comprising the following steps:
(a) hydroxymethylpolystryene resin is reacted with N-protected piperazinic acid to bind it to the resin to produce step (a) product;
(b) the protecting group is removed from the .beta.-nitrogen of the step (a) product to produce step (b) product;
(c) the step (b) product is reacted with R4-boronic acid and glyoxylic acid to produce (c) product;
(d) the step (c) product is reacted with amine R5-NH2 to produce step (d) product;
(e) the step (d) product is deprotected to produce step (e) product;
(f) the step (e) product is reacted with a N-protected .alpha.-amino acid to produce step (f) product;
(g) the protecting group of the .alpha.-amino acid of the step (f) product is removed to produce step (g) product;
(h) the step (g) product is cleaved from the resin and cyclized to produce the compound.
8. The process of Claim 9 characterized in that:
(a) step (c) comprises swelling the step (b) product in DCM, and carrying out the reaction in MeOH solvent;
(b) step (d) comprises swelling the step (c) product in DMF, contacting it with HOBt which acts as an activating agent, and contacting it with DIC which acts as a coupling agent;
(c) step (f) comprises swelling the step (e) product in DMF, contacting it with PyBOP
which acts as a coupling agent, and a base DiPEA, and then the amino acid;
(d) step (h) comprises use of a solution of 5-20% AcOH in iPrOH.
9. A library of compounds of any of Claims 1, 3, 4, 8 or 9.
10. A library of compounds made using the process of Claim 9.
CA002393759A 1999-12-21 2000-12-20 Peptide .beta.-turn mimetic compounds and processes for making them Abandoned CA2393759A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17282399P 1999-12-21 1999-12-21
US60/172,823 1999-12-21
PCT/US2000/034832 WO2001046197A1 (en) 1999-12-21 2000-12-20 PEPTIDE β-TURN MIMETIC COMPOUNDS AND PROCESSES FOR MAKING THEM

Publications (1)

Publication Number Publication Date
CA2393759A1 true CA2393759A1 (en) 2001-06-28

Family

ID=22629385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002393759A Abandoned CA2393759A1 (en) 1999-12-21 2000-12-20 Peptide .beta.-turn mimetic compounds and processes for making them

Country Status (16)

Country Link
EP (1) EP1240169A1 (en)
JP (1) JP2003518124A (en)
KR (1) KR20020062352A (en)
CN (1) CN1413214A (en)
AU (1) AU2286401A (en)
BR (1) BR0016518A (en)
CA (1) CA2393759A1 (en)
CO (1) CO5251420A1 (en)
CZ (1) CZ20022110A3 (en)
HU (1) HUP0300100A2 (en)
IL (1) IL149834A0 (en)
MX (1) MXPA02006330A (en)
NO (1) NO20022953L (en)
PE (1) PE20010955A1 (en)
PL (1) PL355971A1 (en)
WO (1) WO2001046197A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020139044A1 (en) * 2018-12-27 2020-07-02 홀로스메딕 주식회사 Novel compound and pharmaceutical composition comprising same for enhancing anticancer activity
US20220064171A1 (en) * 2018-12-27 2022-03-03 Holosmedic Novel compound and pharmaceutical composition comprising same for enhancing anticancer activity
CA3159791A1 (en) * 2019-10-31 2021-05-06 Holosmedic Hexahydro-2h-pyrazino[1,2-a]pyrazine-6,9-dione derivatives and pharmaceutical compositions for prevention or treatment of cancer comprising same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929237A (en) * 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6013458A (en) * 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto

Also Published As

Publication number Publication date
MXPA02006330A (en) 2002-12-13
JP2003518124A (en) 2003-06-03
BR0016518A (en) 2002-09-24
KR20020062352A (en) 2002-07-25
NO20022953D0 (en) 2002-06-19
CZ20022110A3 (en) 2002-11-13
WO2001046197A1 (en) 2001-06-28
AU2286401A (en) 2001-07-03
EP1240169A1 (en) 2002-09-18
HUP0300100A2 (en) 2003-05-28
PL355971A1 (en) 2004-05-31
NO20022953L (en) 2002-06-19
PE20010955A1 (en) 2001-10-11
CN1413214A (en) 2003-04-23
CO5251420A1 (en) 2003-02-28
IL149834A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
Golebiowski et al. Solid supported high-throughput organic synthesis of peptide β-turn mimetics via tandem Petasis reaction/diketopiperazine formation
US6433134B1 (en) Peptide nucleic acid precursors and methods of preparing same
US6013458A (en) Reverse-turn mimetics and methods relating thereto
JP2008253251A (en) Nucleic acid analog, diagnostic agent and method for using the same in analysis method
JPH09507487A (en) Systematic modular production of amine-imide and oxazolone-based molecules with selected properties
JP4012145B2 (en) Solid phase synthesis of pyrrole-imidazole polyamide
US20030105103A1 (en) Peptide beta-turn mimetic compounds and processes for making them
Groth et al. N-Terminal peptide aldehydes as electrophiles in combinatorial solid phase synthesis of novel peptide isosteres
Staszewska et al. Direct solid-phase synthesis of quinoxaline-containing peptides
EP0804460A1 (en) Conformationally constrained reverse-turn library and methods relating thereto
JPH11508563A (en) 1,4-benzodiazepine-2,5-dione combination library
CA2393759A1 (en) Peptide .beta.-turn mimetic compounds and processes for making them
US6372885B1 (en) Solid-phase technology for the preparation of amides
Periyalagan et al. A novel synthetic method of peptide nucleic acid (PNA) oligomers using Boc/Cbz‐protected PNA trimer blocks in the solution phase
WO2009139922A2 (en) Peptoid compositions and methods of using the same
Park et al. Hydantoin formation by cyclo-elimination: reactivity difference between Merrifield-and Wang-derived resins
WO2006070737A1 (en) β-BENZYLOXYASPARTIC ACID DERIVATIVE HAVING TWO SUBSTITUENTS ON BENZENE RING
US8674020B2 (en) Process for preparing polyamides
Bhatt et al. Efficient one-pot HATU mediated coupling of dicarboxylic acid and amines for the synthesis of diamide at ambient temperature
WO2001055091A1 (en) Solid-supported process for making n-substituted peptide mimetic compounds
Hung et al. Use of ‘click chemistry’for the synthesis of tetrazole-containing analogues of the neuroprotective agent glycyl-L-prolyl-L-glutamic acid
WO2005100378A1 (en) Process for the preparation of a peptide, and compounds comprising a thioester carboxyl-activating group for use therein
AU2004249363A1 (en) Libraries containing heterocyclic organic molecules prepared through intramolecular formation of N-acyliminium ions
CA2579631C (en) Selectively cleavable linkers based on iminodiacetic acid ester bonds
AU705844B2 (en) Combinatorial 1,4-benzodiazepin-2, 5-dione library

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued